27 July 2026
27 July 2026
Outlook’s approval brings the first ophthalmic formulation of bevacizumab for the treatment of wet AMD.
While amlitelimab elicited durable responses in AD, Sanofi does not believe the drug is meaningfully differentiated from current eczema treatment offerings.
The combined formulation begins working in under 30 minutes and delivers pain relief for up to 12 hours.
Despite a crowded landscape, there are significant clinical unmet needs in epilepsy treatment.
RushData incorporates antibody expression, binding analysis, and early developability profiling within one standardised workflow.
The new investment increases BeOne Medicines’ total spend on US manufacturing facilities to over $1bn.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
